Press "Enter" to skip to content

Novartis gets U.S. approval for new drug to treat multiple sclerosis

Novartis AG won U.S. Food and Drug Administration approval on Tuesday for its new multiple sclerosis drug Mayzent, as the Swiss drugmaker seeks to tap a new group of patients in whom the neurological disease has shifted from intermittent attacks to a gradually worsening progression.

Also Read:   Family behind Purdue Pharma pushed opioid marketing, Massachusetts says